Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Precirix has raised $88.2M in total funding. The most recent round was Series B. The last funding was announced in March 2022.
Precirix's investors include Novo Holdings, Jeito Capital, Inkef, HealthCap, Forbion Capital Partners.
Precirix is headquartered in Brussels, Belgium.
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Precirix is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Precirix — Funding & Investors." VCBacked, March 16, 2022, https://www.vcbacked.co/company/precirix. Accessed August 8, 2026.
VCBacked. (2022). Precirix — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/precirix
{{cite web |title=Precirix — Funding & Investors |url=https://www.vcbacked.co/company/precirix |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated